As per the terms of the deal, Evotech is eligible to pay a sum of $10m as an upfront payment from Roche.
Additionally, Evotec is eligible to get further development and milestone payments up to $820m and tiered double-digit royalties on sales from Roche.
The tie up allows Roche to begin studies in 2012 to demonstrate proof of concept and will be responsible for all clinical development, manufacturing and commercialization activities.
Roche Pharma Research & Early Development head the addition of EVT-302 to their CNS pipeline complements other approaches they are investigating including tau- and amyloid- targeted therapies.